Clinical trial
Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea
NCT02010788 is registered in ClinicalTrials.gov with Allergan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea
- Lead sponsor
- Allergan
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 28, 2014
- Completion date
- July 31, 2016
- Enrollment
- 523 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.